Avastin advertising contracted before FDA decision

12/13/2011 | Medical Marketing & Media

Roche's Genentech unit reduced spending on journal ads for Avastin well before the FDA revoked approval for the drug to treat breast cancer. Genentech stopped promoting Avastin for breast cancer in August 2010 and reduced spending on journal ads for other indications in 2011, a spokeswoman said.

View Full Article in:

Medical Marketing & Media

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC